Log in

GlaxoSmithKline SEC Filings & 10K Form (NYSE:GSK)

$43.08
+0.32 (+0.75 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$42.76
Now: $43.08
$43.20
50-Day Range
$42.76
MA: $46.04
$47.89
52-Week Range
$38.43
Now: $43.08
$48.25
Volume3.83 million shs
Average Volume3.32 million shs
Market Capitalization$107.50 billion
P/E Ratio18.10
Dividend Yield4.61%
Beta0.71

SEC Filings

GlaxoSmithKline (NYSE:GSK) SEC Filings

DateFilerForm TypeView
02/21/2020
7:23 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/20/2020
10:16 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/20/2020
8:44 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/20/2020
8:41 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/19/2020
12:16 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/19/2020
11:43 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/19/2020
11:34 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/19/2020
11:09 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/19/2020
11:03 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/18/2020
3:35 PM
GlaxoSmithKline (Filed by)
Morphic Holding, Inc. (Subject)
Form SC 13D/A
02/12/2020
12:30 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/11/2020
9:49 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/11/2020
6:06 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2020
12:39 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/05/2020
12:36 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/03/2020
10:31 AM
GlaxoSmithKline (Filer)
Form 6-K/A
02/03/2020
5:01 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/15/2020
6:10 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/14/2020
12:40 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/14/2020
12:23 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/13/2020
1:10 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/13/2020
10:06 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/13/2020
8:55 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/13/2020
8:41 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/08/2020
11:28 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/08/2020
11:23 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/02/2020
8:08 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/23/2019
7:29 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/20/2019
3:46 PM
GlaxoSmithKline (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
12/18/2019
12:48 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/18/2019
11:43 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/17/2019
6:38 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/13/2019
11:36 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/11/2019
12:20 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/05/2019
6:41 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/02/2019
1:37 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/02/2019
1:27 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/26/2019
12:33 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/12/2019
10:35 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/08/2019
12:38 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/06/2019
11:00 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/04/2019
12:18 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/01/2019
1:21 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/01/2019
11:28 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/31/2019
5:27 PM
GlaxoSmithKline (Reporting)
Progyny, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2019
10:26 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/30/2019
1:20 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/30/2019
12:54 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/24/2019
7:36 PM
GlaxoSmithKline (Reporting)
Progyny, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
10/22/2019
4:36 PM
GlaxoSmithKline (Reporting)
Principia Biopharma Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/21/2019
5:34 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2019
12:07 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2019
12:00 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2019
11:54 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2019
11:50 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/11/2019
12:31 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/11/2019
11:40 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/10/2019
11:29 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/01/2019
12:49 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/01/2019
10:38 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2019
10:10 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2019
6:00 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/26/2019
12:47 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2019
12:25 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/12/2019
3:18 PM
GlaxoSmithKline (Reporting)
Turning Point Therapeutics, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2019
11:32 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/04/2019
12:56 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/04/2019
8:50 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/04/2019
8:37 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/03/2019
7:33 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/23/2019
7:28 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/22/2019
5:49 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/21/2019
6:07 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/12/2019
10:42 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/01/2019
12:10 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/01/2019
11:13 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/01/2019
7:35 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/30/2019
12:43 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2019
11:15 PM
GlaxoSmithKline (Filer)
Form EFFECT
07/29/2019
8:51 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/25/2019
2:39 PM
GlaxoSmithKline (Filed by)
Morphic Holding, Inc. (Subject)
Form SC 13D/A
07/24/2019
3:58 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/24/2019
3:01 PM
Fulcrum Therapeutics, Inc. (Issuer)
GlaxoSmithKline (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/24/2019
12:53 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/24/2019
11:04 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/24/2019
10:33 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/24/2019
5:38 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/22/2019
11:37 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/19/2019
1:03 PM
GlaxoSmithKline (Subject)
JPMorgan Chase Bank, N.A. - ADR Depositary (Filed by)
Form F-6
Registration statement under the Securities Act of 1933 for depositary shares evidenced by American depositary receipts  
07/17/2019
6:37 PM
Fulcrum Therapeutics, Inc. (Issuer)
GlaxoSmithKline (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
07/15/2019
4:27 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2019
4:07 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2019
1:07 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2019
9:29 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2019
7:11 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/12/2019
3:23 PM
GlaxoSmithKline (Filed by)
Morphic Holding, Inc. (Subject)
Form SC 13D
07/12/2019
12:12 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/12/2019
12:04 PM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2019
10:59 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2019
5:16 AM
GlaxoSmithKline (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel